{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:49:23Z","timestamp":1790099363581,"version":"4.0.1"},"reference-count":40,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to assess the effects of preventive migraine treatment with atogepant vs. placebo on patient-reported quality of life and functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Analyses of patient-reported outcomes from three 12-week, randomized, placebo-controlled trials evaluating preventive migraine treatment with atogepant 60 mg once-daily: ADVANCE (low-frequency episodic migraine [LFEM], 4\u20138 monthly migraine days [MMDs] and high-frequency episodic migraine [HFEM], 8\u201314 MMDs), PROGRESS (chronic migraine, CM) and ELEVATE (episodic migraine in those previously failed by two to four classes of oral preventive treatments).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Least squares mean differences (95% confidence interval (CI)) in change from baseline were greater ( p\u2009&lt;\u20090.05) for atogepant vs. placebo for Migraine-Specific Quality of Life questionnaire Role Function\u2013Restrictive domain scores at week 12 (ADVANCE: LFEM 12.0 (95% CI = 6.0\u201318.0), HFEM 9.9 (95% CI = 3.4\u201316.4); PROGRESS: 6.2 (95% CI = 2.5\u20139.8); ELEVATE: 17.7 (95% CI = 13.1\u201322.3)), for Headache Impact Test-6 total scores at week 12 (ADVANCE: LFEM \u22124.7 (95% CI = \u22126.7 to \u22122.7); HFEM \u22123.4 (95% CI = \u22125.5 to \u22121.2); PROGRESS: \u22122.8 (95% CI = \u22124.1 to \u22121.4); ELEVATE: \u22126.5 (95% CI = \u22128.3 to \u22124.7)) and for Activity Impairment in Migraine\u2013Diary-Performance of Daily Activities scores across 12 weeks (ADVANCE: LFEM \u22122.3 (95% CI = \u22123.9 to \u22120.7), HFEM \u22124.5 (95% CI = \u22126.9 to \u22122.2); PROGRESS: \u22123.4 (95% CI = \u22125.3 to \u22121.5); ELEVATE: \u22124.7 (95% CI = \u22126.4 to \u22123.1)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preventive migraine treatment with atogepant 60 mg once-daily vs. placebo improved measures of migraine-related quality of life and functioning among participants with different headache frequencies and histories of previous treatment failure. Trial Registration: ClinicalTrials.gov: NCT03777059 (ADVANCE); NCT03855137 (PROGRESS); NCT04740827 (ELEVATE)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024241300305","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T02:17:42Z","timestamp":1733710662000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized,  phase 3 trials"],"prefix":"10.1177","volume":"44","author":[{"given":"Christopher","family":"Gottschalk","sequence":"first","affiliation":[{"name":"Yale Medicine Department of Neurology, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8317-7712","authenticated-orcid":false,"given":"Pranav","family":"Gandhi","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[{"name":"Headache Unit, Department of Neurology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Christie","sequence":"additional","affiliation":[{"name":"University of Ottawa, Neurology, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2113","authenticated-orcid":false,"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[{"name":"Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy"},{"name":"IRCCS C. Mondino Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Stokes","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Luo","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztian","family":"Nagy","sequence":"additional","affiliation":[{"name":"AbbVie, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,8]]},"reference":[{"key":"bibr1-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.13301"},{"key":"bibr2-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"bibr3-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0946-z"},{"key":"bibr4-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr5-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.13421"},{"key":"bibr6-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03068.x"},{"key":"bibr7-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.192492"},{"key":"bibr8-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02223.x"},{"key":"bibr9-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87352-2"},{"key":"bibr10-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.13966"},{"key":"bibr11-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.14154"},{"key":"bibr12-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416636055"},{"key":"bibr13-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00331-3"},{"key":"bibr14-03331024241300305","unstructured":"Qulipta [package insert]: AbbVie, 2023."},{"key":"bibr15-03331024241300305","unstructured":"AbbVie announces European Commission Approval of AQUIPTA(R) (atogepant) for the preventive treatment of migraine in adults [press release], https:\/\/news.abbvie.com\/2023-08-17-AbbVie-Announces-European-Commission-Approval-of-AQUIPTA-R-atogepant-for-the-Preventive-Treatment-of-Migraine-in-Adults (2023, accessed 23 October 2024)."},{"key":"bibr16-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"bibr17-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.14439"},{"key":"bibr18-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01049-8"},{"key":"bibr19-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00025-5"},{"key":"bibr20-03331024241300305","unstructured":"Guideline on clinical investigation of medicinal products for the treatment of migraine, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-migraine_en.pdf (2007, accessed 23 October 2024)."},{"key":"bibr21-03331024241300305","unstructured":"US Food and Drug Administration. Migraine: developing drugs for preventive treatment. Guidance for Industry, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/migraine-developing-drugs-preventive-treatment (2023, accessed 23 October 2024)."},{"key":"bibr22-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001267"},{"key":"bibr23-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01997.x"},{"key":"bibr24-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"bibr25-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.14229"},{"key":"bibr26-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.14521"},{"key":"bibr27-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201568"},{"key":"bibr28-03331024241300305","first-page":"333102423119029","volume":"51","author":"Lipton RB","year":"2023","journal-title":"Cephalalgia"},{"key":"bibr29-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0230-7"},{"key":"bibr30-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00950.x"},{"key":"bibr31-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01852.x"},{"key":"bibr32-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413497599"},{"key":"bibr33-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.05.010"},{"key":"bibr34-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-010-0175-6"},{"key":"bibr35-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"bibr36-03331024241300305","first-page":"927","volume":"95","author":"Caronna E","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"bibr37-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201566"},{"key":"bibr38-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043242"},{"key":"bibr39-03331024241300305","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.7090"},{"key":"bibr40-03331024241300305","unstructured":"National Institute of Neurological Disorders and Stroke. Summary of core supplemental\u2014highly recommended recommendations: headache CDEs, https:\/\/commondataelements.ninds.nih.gov\/sites\/nindscde\/files\/Doc\/Headache\/CDEStartupResource_Headache.pdf (2023, accessed 23 October 2024)."}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024241300305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024241300305","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024241300305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:09Z","timestamp":1777387569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024241300305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/03331024241300305"],"URL":"https:\/\/doi.org\/10.1177\/03331024241300305","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"article-number":"03331024241300305"}}